VET-STEM

VetStem Biopharma, founded in 2002, is a leading veterinary regenerative medicine company based near San Diego, California. The company specializes in providing stem cell therapy services for companion animals, primarily dogs, cats, and horses. VetStem's core technology involves processing adipose-derived stem cells from a patient's own fat tissue to treat various conditions, including osteoarthritis, tendon and ligament injuries, and other degenerative diseases.

VetStem pioneered the use of autologous veterinary adipose-derived stem cells in 2003, with the first successful treatment of a horse for a tendon injury. The company expanded its services to include treatments for dogs and cats in 2007. VetStem operates a GMP-compliant cell therapy manufacturing facility at its headquarters in Poway, California, which was opened in February 2017. This facility produces stem cell products for use in VetStem's FDA product development programs and is designed to produce commercial products once approved by the FDA.

The company's stem cell processing service involves collecting a small sample of fat tissue from the patient, which is then sent to VetStem's laboratory for processing. The extracted stem cells are concentrated and can be used immediately for treatment or cryopreserved for future use. VetStem also offers Veterinary Platelet Enhancement Therapy (V-PET), which uses the patient's platelets to stimulate tissue repair.

As of 2024, VetStem is in the final phase of FDA testing for its first product, a canine osteoarthritis therapy, which is expected to receive FDA approval within the next two years. The company holds exclusive licenses to more than 70 patents in the field of regenerative medicine and continues to investigate stem cell therapy for various conditions, including immune-mediated and inflammatory diseases, as well as organ disease and failure.